- Home
- BHAT vs GLTO Comparison
BHAT vs GLTO Comparison
Compare BHAT & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHAT
- GLTO
- Stock Information
- Founded
- BHAT 2010
- GLTO 2011
- Country
- BHAT China
- GLTO Denmark
- Employees
- BHAT N/A
- GLTO N/A
- Industry
- BHAT Recreational Games/Products/Toys
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- BHAT Consumer Discretionary
- GLTO Health Care
- Exchange
- BHAT Nasdaq
- GLTO Nasdaq
- Market Cap
- BHAT 12.3M
- GLTO 4.5M
- IPO Year
- BHAT 2019
- GLTO 2020
- Fundamental
- Price
- BHAT $1.66
- GLTO $2.85
- Analyst Decision
- BHAT
- GLTO Buy
- Analyst Count
- BHAT 0
- GLTO 1
- Target Price
- BHAT N/A
- GLTO $10.00
- AVG Volume (30 Days)
- BHAT 1.1M
- GLTO 251.4K
- Earning Date
- BHAT 04-30-2025
- GLTO 10-31-2025
- Dividend Yield
- BHAT N/A
- GLTO N/A
- EPS Growth
- BHAT N/A
- GLTO N/A
- EPS
- BHAT N/A
- GLTO N/A
- Revenue
- BHAT $18,724,190.00
- GLTO N/A
- Revenue This Year
- BHAT N/A
- GLTO N/A
- Revenue Next Year
- BHAT N/A
- GLTO N/A
- P/E Ratio
- BHAT N/A
- GLTO N/A
- Revenue Growth
- BHAT N/A
- GLTO N/A
- 52 Week Low
- BHAT $1.51
- GLTO $2.01
- 52 Week High
- BHAT $45.00
- GLTO $14.56
- Technical
- Relative Strength Index (RSI)
- BHAT 46.47
- GLTO 41.84
- Support Level
- BHAT $1.62
- GLTO $2.53
- Resistance Level
- BHAT $1.83
- GLTO $3.99
- Average True Range (ATR)
- BHAT 0.18
- GLTO 0.33
- MACD
- BHAT 0.01
- GLTO -0.02
- Stochastic Oscillator
- BHAT 18.00
- GLTO 25.97
About BHAT Blue Hat Interactive Entertainment Technology
Blue Hat Interactive Entertainment Technology is focused on commodity trading, including chemicals, jewelry, and precious metals such as gold. It operates a gold and diamond trading and supply chain business. Its business model encompasses physical gold trading, diamond trading, gold derivatives trading, and the development of AI-enabled trading platforms. Its segments include Diamond trading, Commodity trading, Information service, Interactive toys - animation series, and Interactive toys - game series. It derives revenue from Diamond trading. The majority of its revenues are generated in PRC.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.